BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16939699)

  • 1. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
    Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
    Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
    Tomera KM
    Expert Rev Mol Diagn; 2004 Nov; 4(6):783-94. PubMed ID: 15525221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
    Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
    Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
    Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
    Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
    Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
    Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
    Kurokawa S; Morita T; Muraishi O; Tokue A
    Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.